1. Decoding the complexity of benign prostatic hyperplasia therapies in the PARTEM trial;Lopategui;Lancet Reg Health Eur,2024
2. Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre, open-label, phase 3, superiority trial;Sapoval;Lancet Reg Health Eur,2023
3. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study;Roehrborn;Eur Urol,2010
4. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia;McConnell;N Engl J Med,2003
5. Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study;Ayele;World J Urol,2021